Myriad Genetics, Inc. (MYGN) Tops Q2 EPS by 4c, Boosts Guidance

February 5, 2013 4:31 PM EST Send to a Friend
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q2 EPS of $0.42, $0.04 better than the analyst estimate of $0.38. Revenue for the quarter came in at $149.1 million versus the consensus estimate of $143.71 million.

Myriad Genetics, Inc. sees FY2013 EPS of $1.55-1.58, versus the consensus of $1.54. Myriad Genetics, Inc. sees FY2013 revenue of $575-585 million, versus prior guidance of $570-585 million and the consensus of $580.06 million.

For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment